On February 11, 2020, IntelGenx Technologies Corp. (the "Corporation") reported that it has entered into a warrant indenture (the "Warrant Indenture") with TSX Trust Company (the "Warrant Agent") (Filing, 8-K, IntelGenx, FEB 11, 2020, View Source [SID1234554196]). Pursuant to the Warrant Indenture, the Corporation issued an aggregate principal amount of CA$8,158,500 of units ("Units") at a price of CA$0.50 per Unit, each of which consists of one share of the Corporation’s common stock ("Common Stock") and one Common Stock purchase warrant ("Warrant"). Each Warrant is exercisable to purchase one share of the Corporation’s Common Stock ("Warrant Share") at an exercise price of CA$0.75 per Warrant Share, subject to adjustment. The Warrants are immediately exercisable and will expire at 5:00 p.m. (eastern time) on February 11, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Warrant Indenture contains customary terms and conditions for the issuance, transfer and exercise of the Warrants and the terms governing actions taken by the Warrant holders and the obligations of the Corporation and the Warrant Agent in relation to the Warrants. The Warrant Indenture provides that in the event there is a subdivision, redivision, reduction, combination, consolidation or other change of the shares of Common Stock into a greater or lesser number of shares of Common Stock or securities of the Corporation, the exercise price of the Warrants and the number of the Warrant Shares issuable upon conversion of the Warrants will be adjusted accordingly.